{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-010790","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-05-15T13:25:40+00:00","discovered_at":"2026-05-15T13:27:00.288320+00:00","generated_at":"2026-05-15T13:28:58.582408+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix reports Phase 1 PK data for TNX-4800 Lyme antibody; two-dose regimen supports 6-month protection","bullets":["TNX-4800 Phase 1 PK data presented at Global Lyme Alliance; two-dose 350 mg SC regimen (Day 1, Day 56) modeled.","Simulations predict days above MEC: 10 µg/mL (196 days), 15 µg/mL (161 days), 20 µg/mL (136 days), 5 µg/mL (265 days).","Data supports maintaining serum level above 10 µg/mL for six months after initial dose, proposed Phase 2 primary endpoint.","Adaptive Phase 2 field study planned for first half of 2027, pending FDA agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-010790","json":"https://secwatch.observer/filing/0001999371-26-010790.json","markdown":"https://secwatch.observer/filing/0001999371-26-010790.md","text":"https://secwatch.observer/filing/0001999371-26-010790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010790/0001999371-26-010790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010790/tnxp-8k_051526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:28:58.582408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}